Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05194995 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Dec 2025 to Apr 30, 2025
    • Study completion date: Jan 2026 to Dec 2026
    v9
  2. Study Identification, Study Status, Contacts/Locationsv8
  3. Lead sponsor: Jacobio Pharmaceuticals Co., Ltd. to Allist Pharmaceuticals, Inc.
    • Primary completion date: Dec 2024 to Dec 2025
    v7
  4. Primary completion date: Dec 2023 to Dec 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 62 to confirmed 48
    • Study sites: 29 to 17
    v6
  5. Study sites: 32 to 29v5
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 31 to 32v4
  2. Study sites: 12 to 31v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2022 to Feb 17, 2022
    • Site details revised at 12 of 12 sites
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of JAB-21822 in combination with cetuximab in patients with advanced colorectal cancer，advanced small intestine cancer and advanced appendiceal cancer with KRAS p.G12C mutation.
Trial Details
NCT Number NCT05194995
Lead Sponsor Allist Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer
Related terms Appendiceal Neoplasms
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov